Inclusive Lambda Production in Two-Photon Collisions at LEP

The reactions e^+e^- -> e^+e^- Lambda X and e^+e^- -> e^+e^- Lambda X are studied using data collected at LEP with the L3 detector at centre-of-mass energies between 189 and 209 GeV. Inclusive differential cross sections are measured as a function of the lambda transverse momentum, p_t, and pseudo-rapidity, eta, in the ranges 0.4 GeV < p_t < 2.5 GeV and |\eta| < 1.2. The data are compared to Monte Carlo predictions. The differential cross section as a function of p_t is well described by an exponential of the form A exp (- p_t / )$

Inclusive Jet Production in Two-Photon Collisions at LEP

Inclusive jet production, e+e- -> e+e- \ee$ jet X, is studied using 560/pb of data collected at LEP with the L3 detector at centre-of-mass energies between 189 and 209 GeV. The inclusive differential cross section is measured using a k_t jet algorithm as a function of the jet transverse momentum, pt, in the range 3<pt<50 GeV for a pseudorapidity, eta, in the range -1<eta<1. This cross section is well represented by a power law. For high pt, the measured cross section is significantly higher than the NLO QCD predictions, as already observed for inclusive charged and neutral pion production

Measurement of the Isolated Photon Cross Section in p-pbar Collisions at sqrt{s}=1.96 TeV

The cross section for the inclusive production of isolated photons has been measured in p anti-p collisions at sqrt{s}=1.96 TeV with the D0 detector at the Fermilab Tevatron Collider. The photons span transverse momenta 23 to 300 GeV and have pseudorapidity |eta|<0.9. The cross section is compared with the results from two next-to-leading order perturbative QCD calculations. The theoretical predictions agree with the measurement within uncertainties.Comment: 7 pages, 5 figures, submitted to Phys.Lett.

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

_Background_ This open-label, first-in-human, phase 1 study evaluated AMG 232, an oral selective MDM2 inhibitor in patients with TP53 wild-type (P53WT), advanced solid tumors or multiple myeloma (MM). _Methods_ In the dose escalation (n = 39), patients with P53WT refractory solid tumors enrolled to receive once-dailyAMG 232 (15, 30, 60, 120, 240, 480, and 960 mg) for seven days every 3 weeks (Q3W). In the dose expansion (n = 68), patients with MDM2-amplified (well-differentiated and dedifferentiated liposarcomas [WDLPS and DDLPS], glioblastoma multiforme [GBM], or other solid tumors [OST]), MDM2-overexpressing ER+ breast cancer (BC), or MM received AMG 232 at the maximum tolerated dose (MTD). Safety, pharmacokinetics, pharmacodynamics, and efficacy were assessed. _Results_ AMG 232 had acceptable safety up to up to 240 mg

Heavy quarkonium: progress, puzzles, and opportunities

A golden age for heavy quarkonium physics dawned a decade ago, initiated by the confluence of exciting advances in quantum chromodynamics (QCD) and an explosion of related experimental activity. The early years of this period were chronicled in the Quarkonium Working Group (QWG) CERN Yellow Report (YR) in 2004, which presented a comprehensive review of the status of the field at that time and provided specific recommendations for further progress. However, the broad spectrum of subsequent breakthroughs, surprises, and continuing puzzles could only be partially anticipated. Since the release of the YR, the BESII program concluded only to give birth to BESIII; the $B$-factories and CLEO-c flourished; quarkonium production and polarization measurements at HERA and the Tevatron matured; and heavy-ion collisions at RHIC have opened a window on the deconfinement regime. All these experiments leave legacies of quality, precision, and unsolved mysteries for quarkonium physics, and therefore beg for continuing investigations. The plethora of newly-found quarkonium-like states unleashed a flood of theoretical investigations into new forms of matter such as quark-gluon hybrids, mesonic molecules, and tetraquarks. Measurements of the spectroscopy, decays, production, and in-medium behavior of c\bar{c}, b\bar{b}, and b\bar{c} bound states have been shown to validate some theoretical approaches to QCD and highlight lack of quantitative success for others. The intriguing details of quarkonium suppression in heavy-ion collisions that have emerged from RHIC have elevated the importance of separating hot- and cold-nuclear-matter effects in quark-gluon plasma studies. This review systematically addresses all these matters and concludes by prioritizing directions for ongoing and future efforts.Comment: 182 pages, 112 figures. Editors: N. Brambilla, S. Eidelman, B. K. Heltsley, R. Vogt. Section Coordinators: G. T. Bodwin, E. Eichten, A. D. Frawley, A. B. Meyer, R. E. Mitchell, V. Papadimitriou, P. Petreczky, A. A. Petrov, P. Robbe, A. Vair

Measurement of the Charm Production Cross Section in gamma gamma Collisions at LEP

Open charm production in gamma-gamma collisions is studied with data collected at e+e- centre-of-mass energies from 189 GeV to 202 GeV corresponding to a total integrated luminosity of 410 pb-1. The charm cross section sigma(gamma gamma ---> c c~ X) is measured for the first time as a function of the two-photon centre-of-mass energy in the interval from 5 GeV to 70 GeV and is compared to NLO QCD calculations

Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report

Purpose To determine impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy (BSO) on gynecological cancer incidence and death in heterozygotes of pathogenic MMR (path_MMR) variants. Methods The Prospective Lynch Syndrome Database was used to investigate the effects of gynecological risk-reducing surgery (RRS) at different ages. Results Risk-reducing hysterectomy at 25 years of age prevents endometrial cancer before 50 years in 15%, 18%, 13%, and 0% of path_MLH1, path_MSH2, path_MSH6, and path_PMS2 heterozygotes and death in 2%, 2%, 1%, and 0%, respectively. Risk-reducing BSO at 25 years of age prevents ovarian cancer before 50 years in 6%, 11%, 2%, and 0% and death in 1%, 2%, 0%, and 0%, respectively. Risk-reducing hysterectomy at 40 years prevents endometrial cancer by 50 years in 13%, 16%, 11%, and 0% and death in 1%, 2%, 1%, and 0%, respectively. BSO at 40 years prevents ovarian cancer before 50 years in 4%, 8%, 0%, and 0%, and death in 1%, 1%, 0%, and 0%, respectively. Conclusion Little benefit is gained by performing RRS before 40 years of age and premenopausal BSO in path_MSH6 and path_PMS2 heterozygotes has no measurable benefit for mortality. These findings may aid decision making for women with LS who are considering RRS.Hereditary cancer genetic

Examining sources of individual variation in sustained attention

Sustained attention and psychomotor reactions are foundational components of performance in many laboratory and applied tasks. In sleep research studies, individual differences in baseline attentional vigilance are compounded by individual differences in vulnerability to the negative consequences of fatigue due to sleep loss, producing large differences in reaction time profiles. In this paper, we present a theory and model to explain individual differences in reaction time performance in a sustained attention task, both at baseline and as overall alertness declines across 88 hrs without sleep. The model captures the performance of individual human participants, and illustrates how individual differences in processing speed and differences in susceptibility to fatigue from sleep loss may combine to produce unique performance profiles